openPR Logo
Press release

Biosimilar Pipeline Analysis Market 2018 Revenue And Key Players Pfizer Inc., Biocon, F. Hoffmann-La Roche Ltd, Amgen Inc., Kyowa Pharmaceutical Industry Co. Ltd, Boehringer Ingelheim GmbH, AstraZeneca, Novartis AG, and Merck & Co

02-11-2019 08:46 AM CET | Health & Medicine

Press release from: Coherent Market Insights

Biosimilar Pipeline Analysis Market

Biosimilar Pipeline Analysis Market

Biosimilar is a type of biological product that is almost identical to the original product, which has undergone patent expiration. Development and validation of biosimilars are an important part of the overall production process. Regulation for biosimilar drugs plays an important role in maintaining the efficiency and balance between original and biosimilar drugs. There are various authorities such as U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), which regulate the development and commercialization of biosimilars.

Biosimilar drugs are available at relatively low prices as compared to patented drugs without compromising on efficacy.There are various patented drugs available in the market, with certain drugs such as Adalimumab, the high cost of these drugs directed the biosimilar market. There are few drugs, which are under the last phase of clinical trial are BI695502 developed by Boehringer Ingelheim, PF- 06439535 by Pfizer, Biosimilar bevacizumab by Biocon, and FKB238 by Kyowa Pharmaceutical Industry Co. Increased R&D is expected to support the growth of biosimilar pipeline analysis market.

Get Exclusive Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/582

Biosimilar Pipeline Analysis Market Key Players are Biocon, Pfizer Inc., F. Hoffmann-La Roche Ltd, Amgen Inc., Kyowa Pharmaceutical Industry Co. Ltd, Boehringer Ingelheim GmbH, AstraZeneca, Novartis AG, and Merck & Co.

There is a need for complex infrastructure in the development of biosimilar and lengthy process of clinical trial and approval are the major challenges faced by biosimilar pipeline analysis market. Global biosimilar pipeline analysis market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East and Africa. Europe is expected to dominate the biosimilar pipeline analysis market due to technological advancements in healthcare facilities and regulatory affiliation.

Asia Pacific is expected to closely follow Europe in terms of growth due to increased prevalence of autoimmune disease, cancer, unmet clinical needs of people, and large price conscious population of emerging economies. North America market is expected to grow significantly due to high R&D investments, which supports the growth of biosimilar pipeline analysis market in near future.

Read Full Report with TOC @ https://www.coherentmarketinsights.com/ongoing-insight/toc/582

Biosimilar pipeline analysis market taxonomy:

By Product Type
Human Growth Hormone
Insulin
Interferon
Peptides
Monoclonal antibodies
Others

By Services
Clinical Trials
Contract Research and Manufacturing

By Technology
Electrophoresis
Recombinant DNA Technology
Chromatography
Nuclear Magnetic Resonance Technology
Bioassay
Mass Spectrometry
Western Blotting

By Application
Oncology Disease
Auto immune Disease
Blood Disease
Growth Hormone Deficiencies
Ask Questions to Expertise @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/582

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biosimilar Pipeline Analysis Market 2018 Revenue And Key Players Pfizer Inc., Biocon, F. Hoffmann-La Roche Ltd, Amgen Inc., Kyowa Pharmaceutical Industry Co. Ltd, Boehringer Ingelheim GmbH, AstraZeneca, Novartis AG, and Merck & Co here

News-ID: 1575609 • Views:

More Releases from Coherent Market Insights

Current Sensor Market Set to Witness Significant Growth by 2025-2032 - Coherent Market Insights
Current Sensor Market Set to Witness Significant Growth by 2025-2032 - Coherent …
The Current Sensor market is estimated to be valued at USD 3.42 Bn in 2025 and is expected to reach USD 6.75 Bn by 2032, growing at a compound annual growth rate CAGR of 10.2% from 2025 to 2032. ➤ Coherent Market Insights has published an in-depth research report titled "Current Sensor Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2032." This study offers a deep dive into the Current
U.S. Bodyguard Service & Security Consulting Market Evolution by 2032 - Disruptive Innovations, Regional Insights, and Growth Opportunities
U.S. Bodyguard Service & Security Consulting Market Evolution by 2032 - Disrupti …
The U.S. Bodyguard Service & Security Consulting market is estimated to be valued at USD 2.57 Bn in 2025 and is expected to reach USD 3.52 Bn by 2032, growing at a compound annual growth rate CAGR of 4.6% from 2025 to 2032. ➤ Coherent Market Insights has published an in-depth research report titled "U.S. Bodyguard Service & Security Consulting Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2032." This
Single Cell Sequencing Market Set for Dynamic Boom as Key Players Illumina, BD Biosciences, Pacific Biosciences, Thermo Fisher Scientific
Single Cell Sequencing Market Set for Dynamic Boom as Key Players Illumina, BD B …
The qualitative latest Research report (2025-2032) on the Single Cell Sequencing Market 2025 - 2032 by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves. ➤ Request a Sample
Nuclear Medicine Equipment Market Set for Demonstrate Strong Growth During 2025-2032 with Key Players GE Healthcare, Siemens Healthineers, Philips, and Canon Medical Systems
Nuclear Medicine Equipment Market Set for Demonstrate Strong Growth During 2025- …
The qualitative latest Research report (2025-2032) on the Nuclear Medicine Equipment Market 2025 - 2032 by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves. ➤ Request a Sample

All 5 Releases


More Releases for Biosimilar

Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark …
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030." Get
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031." The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02
Infliximab Biosimilar Insight, 2023 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2023" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of